China's Fosun Pharma in the running for $2b Novartis assets

Shanghai Fosun Pharmaceutical Group Co. is among shortlisted bidders for a portfolio of Novartis AG assets, including its U.S. dermatology business, that could fetch as much as $2 billion, people with knowledge of the matter said.